Watson Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Watson Pharmaceuticals (WPI)
Q2 2012 Earnings Call
July 26, 2012 8:30 am ET
Executives
Lisa M. Defrancesco - Former Vice President of Global Investor RelationsPaul M. Bisaro - Chief Executive Officer, President and DirectorR. Todd Joyce - Chief Financial Officer -GlobalGeorge Frederick Wilkinson - President of Global Brands and BiosimilarsSigurdur Oli Olafsson - President of Global GenericsAnalystsGregory B. Gilbert - BofA Merrill Lynch, Research DivisionDavid Amsellem - Piper Jaffray Companies, Research DivisionMarc Goodman - UBS Investment Bank, Research DivisionDavid G. Buck - The Buckingham Research Group IncorporatedTimothy Chiang - CRT Capital Group LLC, Research DivisionChristopher Schott - JP Morgan Chase & Co, Research DivisionJami Rubin - Goldman Sachs Group Inc., Research DivisionAaron Gal - Sanford C. Bernstein & Co., LLC., Research DivisionElliot Wilbur - Needham & Company, LLC, Research DivisionMichael Faerm - Crédit Suisse AG, Research DivisionKen Cacciatore - Cowen and Company, LLC, Research DivisionGary Nachman - Susquehanna Financial Group, LLLP, Research DivisionMichael Kallai Tong - Wells Fargo Securities, LLC, Research DivisionDavid Risinger - Morgan Stanley, Research DivisionRandall Stanicky - Canaccord Genuity, Research DivisionDouglas D. Tsao - Barclays Capital, Research DivisionShibani Malhotra - RBC Capital Markets, LLC, Research DivisionPresentationOperatorPrevious Statements by WPI
» Watson Pharmaceuticals' CEO Hosts 2012 Annual Shareholders' Meeting (Transcript)
» Watson Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript
» Watson Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
